FDA approves Trulance for chronic idiopathic constipation

The US Food and Drug Administration on Thursday day approved Trulance (plecanatide) for the treatment of chronic idiopathic constipation (CIC) in adult patients.

The drug was developed and will be marketed by Synergy Pharmaceuticals (Nasdaq: SGYP), which says that Trulance will be available in the USA later this quarter. The company’s shares gained 5.5% to $6.76 in after-hours trading.

“No one medication works for all patients suffering from chronic gastrointestinal disorders,” said Julie Beitz, director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research, adding: “With the availability of new therapies, patients and their doctors can select the most appropriate treatment for their condition.”